

## Seagen is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people's lives.

As a pioneer in antibody-drug conjugates (ADCs), Seagen has led the way in novel cancer therapeutics for more than 20 years. This technology is the foundation of two of our approved medicines: ADCETRIS® (brentuximab vedotin) and PADCEV® (enfortumab vedotin-ejfv). ADCETRIS is approved in over 70 countries around the world and continues to make a difference in the lives of patients with several types of lymphomas. In the last year, Seagen successfully launched two new cancer medicines that address significant unmet medical needs.

PADCEV was the first ADC approved for locally advanced or metastatic urothelial (bladder) cancer following treatment with platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor.

Our third medicine is an oral small molecule, TUKYSA® (tucatinib), which was approved in the U.S. for metastatic HER2-positive breast cancer following an expedited FDA review. TUKYSA also has received approval in Australia, Canada, Singapore and Switzerland under the Project Orbis initiative of the FDA Oncology Center of Excellence and is under review with the European Medicines Agency (EMA).

In addition to ADCs, we're also utilizing our expertise in empowered antibodies to build a portfolio of proprietary immuno-oncology agents and expanding the development of our pipeline of novel targeted therapies for solid tumors and blood-related cancers.

## QUICK FACTS

**Year Initiated Operations:** 1998

**Publicly Traded:** Nasdaq: SGEN

**Employees:** >1,850 worldwide

**Passion:** Helping people with cancer

**Leaders in Technology:** Antibody-drug conjugates (ADCs)

**Locations:** Headquartered in Seattle, Washington area; California, Switzerland, and European Union

**Today, our research efforts are dedicated to advancing a pipeline of:**

- Programs using our proprietary ADC technologies
- New classes of ADCs, novel empowered antibodies and other targeted cancer therapies
- ADCs in combination with checkpoint inhibitors

Our pipeline is designed with patients in mind, focusing on therapies that have the potential to address unmet medical needs. See the next page for more details.

Program	Tumor Type	Setting	Treatment	Phase 1	Phase 2	Phase 3
ADCETRIS® (Brentuximab vedotin)	Diffuse large B-cell lymphoma	R/R	+ lenalidomide, rituximab			*
	Hodgkin lymphoma (HL)	1L	+ nivolumab, doxorubicin and dacarbazine			
	HL or PTCL (unfit for combination chemotherapy)	1L	Monotherapy			
	HL and PTCL	R/R	Retreatment			
	HL (pediatrics)	R/R	CheckMate 744: + nivolumab			
	PTCL (< 10% CD30 expression)	1L	+ cyclophosphamide, doxorubicin and prednisone			
	Metastatic solid tumors	R/R	+ pembrolizumab post PD-1			
PADCEV® (Enfortumab vedotin-efv)	Locally advanced or metastatic urothelial cancer	1L	EV-302: + pembrolizumab vs chemotherapy alone			*
			EV-301: Post PD(L)-1 and post platinum chemotherapy	REPORTED POSITIVE TOPLINE RESULTS *		
			EV-201: Cohort 2 post PD(L)-1, platinum naive and cisplatin ineligible	REPORTED POSITIVE TOPLINE RESULTS *		
		1L/2L	EV-103: +/- pembrolizumab		*	
	Muscle invasive bladder cancer	1L	EV-303/KEYNOTE-905: + pembrolizumab			*
		1L	EV-103: +/- pembrolizumab			
	Locally advanced or metastatic solid tumors		EV-202: Monotherapy			
TUKYSA® (Tucatinib)	HER2+ metastatic breast cancer	1L/2L	HER2CLIMB-02: + T-DM1			*
	High risk HER2+ breast cancer		CompassHER2 RD			*
	HER2+ metastatic breast cancer		+ trastuzumab deruxtecan			
	HER2+ metastatic colorectal cancer	R/R	MOUNTAINEER: + trastuzumab		*	
	HER2+ gastroesophageal cancer	2L	MOUNTAINEER-02: + trastuzumab, ramucirumab and chemotherapy			
	Metastatic solid tumors HER2 alterations		+ trastuzumab, +/- fulvestrant			
	HER2+ gastric cancer	1L	+ trastuzumab, oxaliplatin			
Tisotumab vedotin	Metastatic/recurrent cervical cancer		innovaTV 204: Monotherapy	BLA PLANNED 1Q21 *		
		1L/2L	innovaTV 205: + other anti-cancer agents			
	Locally advanced solid tumors		innovaTV 206 (Japan only)			
	Metastatic solid tumors	R/R	innovaTV 207: Monotherapy			
	Platinum-resistant ovarian cancer	2L	innovaTV 208: Monotherapy			
Ladiratumab vedotin	Metastatic triple-negative breast cancer	1L	+ pembrolizumab			
	Metastatic solid tumors	R/R	Monotherapy			
	Metastatic breast cancer (HR+/HER2-)	R/R	+ trastuzumab			
SEA-BCMA	Multiple myeloma	R/R	+/- dexamethasone			
SEA-CD40	Pancreatic cancer	R/R	+/- pembrolizumab, gemcitabine, nap-paclitaxel			
SGN-CD228A	Solid tumors	R/R	Monotherapy			
SEA-CD70	MDS / AML	R/R	Monotherapy			
SEA-TGT	Solid tumors and lymphoma	R/R	+/- pembrolizumab			
SGN-B6A	Solid tumors	R/R	Monotherapy			

1L: front/first-line 2L: second-line R/R: relapsed/refractory PTCL: Peripheral T-cell lymphoma \* Registrational intent